Tidying up business left from last year, Bristol-Myers Squibb has completed the sale of an old-school operation in Italy even as it prepares to move into a whole new...

Amarin scored a massive win last month after the FDA approved its fish-oil derivative Vascepa as a heart-helping addition to statins, potentially setting the drug up...

Johnson & Johnson just got some new ammo for its defense against lawsuits claiming its talc products caused ovarian cancer. As the company fights with plaintif...

Less than a year after buying a U.S. plant from AstraZeneca, Novartis’ biotech AveXis has it ready for production of Zolgensma, its gene therapy for spinal muscular ...

The U.S. Food and Drug Administration today granted accelerated approval to Vyondys 53 (golodirsen) injection to treat Duchenne muscular dystrophy (DMD) patients wh...

AstraZeneca has completed an agreement to divest its commercial rights to Seroquel (quetiapine fumarate immediate release) and Seroquel XR (quetiapine fumarate exte...

Every cell contains a vast number of proteins, each of which has a specific function, for example as a receptor for another molecule or an enzyme that catalyses che...

Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) ("Spark") today announced the completion of the acquisition following the receipt of ...

Clinerion, provider of the Patient Network Explorer platform which harnesses patient data from a global hospital network, and Pangaea, a machine learning company, pa...

Like many a corporate rejuvenation plan, CEO Paul Hudson's blueprint for Sanofi includes some hefty cost cutting. The French drugmaker's aiming for €2 billion in a...